Avata Biosciences
- Biotech or pharma, therapeutic R&D
Avata Biosciences is a privately owned clinical stage pharmaceutical company with lead asset AVAT-021 in clinical development.
Avata’s patented technology platform is able to generate both solid-dose and water-soluble synthetic cannabinoid formulations suitable for targeting CNS diseases with high unmet needs in both adults and children.
The lead asset AVAT-021 will be developed in adult focal-onset seizures (FOS), using the 505(b)(2) regulatory pathway with Epidiolex® as the reference product. Avata has also entered into a partnership with Oxford University to assess AVAT-021, in patients with first episode Schizophrenia.
Avata Biosciences is currently seeking funding for progression of the AVAT-021 clinical development program and is in discussion with venture capital groups, as well as exploring strategic partnering opportunities with pharmaceutical companies.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}